{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:50:04Z","timestamp":1792684204942,"version":"4.5.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Temocillin, a carbapenem-sparing \u03b2-lactam antibiotic, is commonly used at the standard 4 g\/day dosage for treating complicated urinary tract infections (cUTIs). However, pharmacokinetic\/pharmacodynamic (PK\/PD) data supporting this regimen is limited. This study evaluated the plasma pharmacokinetics (PK) and PTA of temocillin in non-critically ill cUTI patients with varying degrees of renal insufficiency (RI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this single-centre clinical study, 22 cUTI patients received a fixed 4 g\/day (2 g q12h, intravenously) temocillin dose, irrespective of renal function (no RI: n\u200a=\u200a5, mild RI: n\u200a=\u200a8, moderate RI: n\u200a=\u200a9). Plasma samples were collected post-dosing for LC-MS analysis of total and unbound temocillin levels. Monte Carlo simulations were performed based on the established PK\/PD target of \u226535% fT\u200a&amp;gt;\u200aMIC (minimal inhibitory concentration).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among patients, the highest plasma drug exposure and PK\/PD target attainment were observed in those with moderate RI (median AUC0\u201312h = 1143 h.mg\/L and %fT\u200a&amp;gt;\u200aMIC\u200a=\u200a68%), followed by mild RI patients (median AUC0\u201312h\u200a=\u200a918 h.mg\/L and %fT\u200a&amp;gt;\u200aMIC\u200a=\u200a34%), and the lowest in those with healthy kidney function (median AUC0\u201312h\u200a=\u200a692 h.mg\/L and %fT\u200a&amp;gt;\u200aMIC\u200a=\u200a26%). Simulations indicated that the 4 g\/day temocillin dose achieves 90% PTA only for glomerular filtration rate\u200a&amp;lt;\u200a60 mL\/min and MIC\u200a\u2264\u200a8 mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The standard temocillin dose may need to be increased from 4 to 6 g\/day to treat non-critically ill cUTI patients, in line with recent EUCAST recommendations. For patients with moderate RI, who experience higher exposure due to reduced renal drug clearance, 4 g\/day temocillin remains appropriate.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae215","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T16:32:01Z","timestamp":1720629121000},"page":"2204-2212","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacokinetics and pharmacological target attainment of standard temocillin dosing in non-critically ill patients with complicated urinary tract infections"],"prefix":"10.1093","volume":"79","author":[{"given":"Gert-Jan","family":"Wijnant","sequence":"first","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrin","family":"Ngougni Pokem","sequence":"additional","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Coessens","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, AZ Delta Hospital , Roeselare , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cottone","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, AZ Delta Hospital , Roeselare , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Ermtraud","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Goeman","sequence":"additional","affiliation":[{"name":"Department of Urology, AZ Delta Hospital , Roeselare , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vervaeke","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, AZ Delta Hospital , Roeselare , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian G","family":"Wicha","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-7991","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Van Bambeke","sequence":"additional","affiliation":[{"name":"Pharmacologie cellulaire et mol\u00e9culaire, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain , Brussels , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"2024090302261583400_dkae215-B1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2024090302261583400_dkae215-B2","doi-asserted-by":"crossref","first-page":"115682","DOI":"10.1016\/j.diagmicrobio.2022.115682","article-title":"Temporal evolution of temocillin susceptibility to Enterobacterales in Belgian hospitals, comments on \u2018Temocillin susceptibility among Enterobacterales strains recovered from blood culture in France\u2019","volume":"103","author":"Miendje Deyi","year":"2022","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024090302261583400_dkae215-B3","doi-asserted-by":"crossref","first-page":"dlac059","DOI":"10.1093\/jacamr\/dlac059","article-title":"In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales","volume":"4","author":"Plambeck","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2024090302261583400_dkae215-B4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S1473-3099(21)00407-2","article-title":"The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden","volume":"22","author":"Edlund","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024090302261583400_dkae215-B5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/antibiotics11040493","article-title":"Temocillin: applications in antimicrobial stewardship as a potential carbapenem-sparing antibiotic","volume":"11","author":"Lupia","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024090302261583400_dkae215-B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11908-018-0613-1","article-title":"Pharmacokinetic\/Pharmacodynamic considerations of beta-lactam antibiotics in adult critically ill patients","volume":"20","author":"Masich","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"2024090302261583400_dkae215-B7","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/jac\/dkab129","article-title":"Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study-authors\u2019 response","volume":"76","author":"Alexandre","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024090302261583400_dkae215-B8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jac\/dkaa486","article-title":"Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study","volume":"76","author":"Alexandre","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024090302261583400_dkae215-B9","doi-asserted-by":"crossref","first-page":"106361","DOI":"10.1016\/j.ijantimicag.2021.106361","article-title":"Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study","volume":"58","author":"Delory","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2024090302261583400_dkae215-B10","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab005","article-title":"Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis","volume":"3","author":"Heard","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2024090302261583400_dkae215-B11","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac086","article-title":"Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study","volume":"4","author":"Oosterbos","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2024090302261583400_dkae215-B12","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.3390\/pharmaceutics14112289","article-title":"Clinical efficacy of temocillin standard dosing in patients treated with outpatient antimicrobial therapy","volume":"14","author":"Van den Broucke","year":"2022","journal-title":"Pharmaceutics"},{"key":"2024090302261583400_dkae215-B13","author":"EUCAST","year":"2024"},{"key":"2024090302261583400_dkae215-B14","author":"Desmet"},{"key":"2024090302261583400_dkae215-B15","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/jac\/dkab081","article-title":"Comment on: efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study","volume":"76","author":"Giske","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024090302261583400_dkae215-B16","author":"EUCAST","year":"2019"},{"key":"2024090302261583400_dkae215-B17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2024090302261583400_dkae215-B18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024090302261583400_dkae215-B19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jac\/11.4.349","article-title":"The pharmacokinetics of temocillin in patients with normal and impaired renal function","volume":"11","author":"Boelaert","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"2024090302261583400_dkae215-B20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00003495-198500295-00023","article-title":"Effect of renal function and dialysis on temocillin pharmacokinetics","volume":"29 Suppl 5","author":"Boelaert","year":"1985","journal-title":"Drugs"},{"key":"2024090302261583400_dkae215-B21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00003495-198500295-00028","article-title":"Temocillin pharmacokinetics in normal and impaired renal function","volume":"29 Suppl 5","author":"H\u00f6ffler","year":"1985","journal-title":"Drugs"},{"key":"2024090302261583400_dkae215-B22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003495-198500295-00027","article-title":"Renal clearance of temocillin in volunteers","volume":"29 Suppl 5","author":"Overbosch","year":"1985","journal-title":"Drugs"},{"key":"2024090302261583400_dkae215-B23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clinbiochem.2015.02.006","article-title":"Validation of a HPLC-MS\/MS assay for the determination of total and unbound concentration of temocillin in human serum","volume":"48","author":"Ngougni Pokem","year":"2015","journal-title":"Clin Biochem"},{"key":"2024090302261583400_dkae215-B24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10928-020-09682-4","article-title":"Assessing parameter uncertainty in small-n pharmacometric analyses: value of the log-likelihood profiling-based sampling importance resampling (LLP-SIR) technique","volume":"47","author":"Broeker","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2024090302261583400_dkae215-B25","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkac286","article-title":"Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications","volume":"77","author":"Ngougni Pokem","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024090302261583400_dkae215-B26","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3390\/microorganisms9071401","article-title":"Optimizing antimicrobial drug dosing in critically ill patients","volume":"9","author":"P\u00f3voa","year":"2021","journal-title":"Microorganisms"},{"key":"2024090302261583400_dkae215-B27","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/jac\/dkaa176","article-title":"Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial","volume":"75","author":"Matzneller","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/9\/2204\/58998510\/dkae215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/9\/2204\/58998510\/dkae215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T02:26:39Z","timestamp":1725330399000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/9\/2204\/7710585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae215","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,10]]}}}